A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Patients who have a life expectancy of at least 12 weeks * Patients with advanced HCC (unresectable, and/or metastatic) which has been histologically or cytologically documented * Patients must have at least one tumor lesion that meets both of the following criteria: * can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST) * has not been previously treated with local therapy * Patients who have received local therapy except chemoembolization, such as surgery, radiation therapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of 25% in the size. Local therapy must be completed at least 4 weeks prior to the baseline scan * Patients who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 Exclusion Criteria: * Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated \> 3 years prior to entry is permitted * History of cardiac disease * Serious myocardial dysfunction * Active, clinically serious infections * Known history of Human Immunodeficiency Virus (HIV) infection * Known Central Nervous System (CNS) tumors including metastatic brain disease * Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry